Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added current date (2025-10-20) and a new Study Status entry (2025-10-10); removed an older date (2025-08-07). This updates time-sensitive content and study status to reflect new information.
    Difference
    0.8%
    Check dated 2025-10-21T01:32:55.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page is updated to reflect a new version (v3.2.0) and to add a prominent notice about government funding lapse and current operating status of NIH Clinical Center; the previous version reference (v3.1.0) was removed.
    Difference
    9%
    Check dated 2025-10-06T15:51:13.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.
    Difference
    0.2%
    Check dated 2025-09-29T09:47:22.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page revision was updated from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed.
    Difference
    0.5%
    Check dated 2025-09-14T23:37:51.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.5%
    Check dated 2025-09-07T20:22:21.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This suggests a shift towards a more generalized presentation of location data.
    Difference
    58%
    Check dated 2025-08-31T13:00:36.000Z thumbnail image

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.